These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20085392)

  • 1. Access with evidence development in the UK: past experience, current initiatives and future potential.
    Briggs A; Ritchie K; Fenwick E; Chalkidou K; Littlejohns P
    Pharmacoeconomics; 2010; 28(2):163-70. PubMed ID: 20085392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access with evidence development schemes: a framework for description and evaluation.
    McCabe CJ; Stafinski T; Edlin R; Menon D;
    Pharmacoeconomics; 2010; 28(2):143-52. PubMed ID: 20085390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.
    Stafinski T; McCabe CJ; Menon D
    Pharmacoeconomics; 2010; 28(2):113-42. PubMed ID: 20085389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Access with evidence development: the US experience.
    Mohr PE; Tunis SR
    Pharmacoeconomics; 2010; 28(2):153-62. PubMed ID: 20085391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?
    Mason A; Drummond M; Ramsey S; Campbell J; Raisch D
    J Clin Oncol; 2010 Jul; 28(20):3234-8. PubMed ID: 20498408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions.
    Walker S; Sculpher M; Claxton K; Palmer S
    Value Health; 2012 May; 15(3):570-9. PubMed ID: 22583469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
    Barbieri M; Hawkins N; Sculpher M
    Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.
    Wallerstedt SM; Henriksson M
    Br J Clin Pharmacol; 2018 Jun; 84(6):1146-1155. PubMed ID: 29381234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving Access to High-Cost Technologies in the Asia Region.
    Mundy L; Trowman R; Kearney B
    Int J Technol Assess Health Care; 2019 Jan; 35(3):168-175. PubMed ID: 31122302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
    Beresniak A; Dupont D
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health economic decision-making: a comparison between UK and Spain.
    Corbacho B; Pinto-Prades JL
    Br Med Bull; 2012 Sep; 103(1):5-20. PubMed ID: 22833571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
    Williams I; McIver S; Moore D; Bryan S
    Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared.
    Cairns J
    Health Policy; 2006 Apr; 76(2):134-43. PubMed ID: 15982779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes.
    Varnava A; Bracchi R; Samuels K; Hughes DA; Routledge PA
    Pharmacoeconomics; 2018 May; 36(5):613-624. PubMed ID: 29520603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug assessment: UK style.
    Drug Ther Bull; 2013 Dec; 51(12):141-4. PubMed ID: 24336496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using health outcomes data to inform decision-making: government agency perspective.
    Taylor R
    Pharmacoeconomics; 2001; 19 Suppl 2():33-8. PubMed ID: 11700787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considering changes to CMS's national coverage decision process: applying lessons learned from FDA as a regulator of access to healthcare technology.
    Zalesky CD
    Food Drug Law J; 2002; 57(1):73-93. PubMed ID: 12118482
    [No Abstract]   [Full Text] [Related]  

  • 19. Advanced Medical Care Program for the Rapid Introduction of Healthcare Technologies to the National Health Insurance System in Japan.
    Ueda K; Sanada S; Uemura N
    Clin Transl Sci; 2020 Jul; 13(4):700-706. PubMed ID: 32004408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug reimbursement policies in Canada--need for improved access to critical therapies.
    LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
    Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.